5-Methoxy-N-methyl-N-isopropyltryptamine, commonly known as 5-MeO-MiPT or moxy, is a lesser-known psychedelic compound belonging to the tryptamine class. Structurally, 5-MeO-MiPT is closely related to other tryptamines, such as 5-MeO-DMT and 5-MeO-DiPT, and it exerts its psychoactive effects primarily through interaction with serotonin receptors in the brain.

The synthesis and pharmacological properties of 5-MeO-MiPT were first documented in 1985 by researchers David Repke and Alexander Shulgin. Its effects on human subjects are discussed in Shulgin’s influential book, TiHKAL.

Anecdotal evidence suggests that 5-MeO-MiPT elicits markedly stimulating and mildly entactogenic effects, while typically lacking the vivid visual distortions commonly associated with other psychedelics. Many users report significant physical and tactile sensations, which can enhance libido and sexual pleasure. However, some also experience an undesirable body load at moderate to high doses, characterized by muscle tension and nausea.

Despite its intriguing effects, there is limited information available regarding the pharmacological properties, metabolism, and toxicity of 5-MeO-MiPT, and its history of human use is not extensive. It has been marketed online as a research chemical, but due to the uncertainties surrounding its safety, it is strongly recommended to implement harm reduction practices for anyone considering its use.